Geisinger Medical Laboratories Test Catalog
ERYTHROCYTE SEDIMENTATION RATE (ESR) |
|||||||||||||||||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB2234 Geisinger Epic ID: 7219 | ||||||||||||||||
SPECIMEN COLLECTION |
|||||||||||||||||
Specimen type: |
Whole blood | ||||||||||||||||
Preferred collection container: |
|||||||||||||||||
Alternate Collection Container: |
Lavender-top (K2 EDTA) microcollection tube
|
||||||||||||||||
Specimen required: |
One (1) lavender-top (K2 EDTA) tube properly filled. Minimum sample volume is 500µL whole blood. | ||||||||||||||||
Special notes: |
If STAT measurement of inflammation needed, perform CRP (C-reactive protein). | ||||||||||||||||
SPECIMEN PROCESSING |
|||||||||||||||||
Specimen processing instructions: |
Do not centrifuge. Specimen must be sent as whole blood. | ||||||||||||||||
Transport temperature: |
Room temperature (GMC) or refrigerated (non-GMC). | ||||||||||||||||
Specimen stability: |
Room temperature: 6 hours. Refrigerated: 24 hours. | ||||||||||||||||
Rejection criteria: |
Clotted, frozen, centrifuged, hemolyzed and improperly filled. Specimens received beyond stability. | ||||||||||||||||
TEST DETAILS |
|||||||||||||||||
Reference interval: |
|
||||||||||||||||
Interpretation guide: |
Interferences:
|
||||||||||||||||
Additional information: |
Turnaround Times
|
||||||||||||||||
CPT code(s): |
85652 | ||||||||||||||||
Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | |||||||||||||||||
Methodology: |
Rheology technology that directly measures rouleaux formation to determine the red cell sedimentation |
||||||||||||||||
Synonyms: |
Sed Rate, ESR, Erythrocyte Sedimentation Rate Sed rate by modified Westergren
|
||||||||||||||||
Clinical significance: |
Nonspecific marker of inflammation, especially in chronic diseases. ESR tends to be elevated in monoclonal blood protein disorders (multiple myeloma), severe polyclonal hyperglobulinemia due to inflammatory disease, and hyperfibrinogenemia. | ||||||||||||||||
Doctoral Director(s:) |
Mary Dhesi MD | ||||||||||||||||
Review Date: | 01/09/2023 |